117
Views
11
CrossRef citations to date
0
Altmetric
Original Research

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab

ORCID Icon, , , , , , ORCID Icon, , , , ORCID Icon & show all
Pages 8049-8056 | Published online: 24 Oct 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Shinsuke Suzuki, Tomoe Abe, Tentaro Endo, Haruka Kaya, Takuro Kitabayashi, Yohei Kawasaki & Takechiyo Yamada. (2022) Association of Pretreatment Neutrophil-to-Eosinophil Ratio with Clinical Outcomes in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab. Cancer Management and Research 14, pages 3293-3302.
Read now
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Akihiro Miura, Hiroki Komori, Kentaro Kuroiwa, Narihito Seki, Naohiro Fujimoto & Motonobu Nakamura. (2022) Association Between Immune-Related Adverse Events and Efficacy and Changes in the Relative Eosinophil Count Among Patients with Advanced Urothelial Carcinoma Treated by Pembrolizumab. Cancer Management and Research 14, pages 1641-1651.
Read now

Articles from other publishers (9)

Satoru Taguchi, Taketo Kawai, Tohru Nakagawa & Haruki Kume. (2024) Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review. Japanese Journal of Clinical Oncology 54:3, pages 254-264.
Crossref
Eiji Takeuchi, Hirokazu Ogino, Kensuke Kondo, Yoshio Okano, Seiya Ichihara, Michihiro Kunishige, Naoki Kadota, Hisanori Machida, Nobuo Hatakeyama, Keishi Naruse, Hiroshi Nokihara, Tsutomu Shinohara & Yasuhiko Nishioka. (2023) An increased relative eosinophil count as a predictive dynamic biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors. Thoracic Cancer 15:3, pages 248-257.
Crossref
Felice Crocetto, Ciro Imbimbo, Biagio Barone, Davide Turchino, Umberto Marcello Bracale, Antonio Peluso, Marco Panagrosso, Alfonso Falcone, Benito Fabio Mirto, Luigi De Luca, Enrico Sicignano, Francesco Del Giudice, Gian Maria Busetto, Giuseppe Lucarelli, Gaetano Giampaglia, Celeste Manfredi, Matteo Ferro & Giovanni Tarantino. (2023) Which inflammatory marker, between systemic immune-inflammation index and neutrophil to eosinophil ratio, is associated with Peyronie’s disease and are there any implications for a better understanding of its mechanisms?. Basic and Clinical Andrology 33:1.
Crossref
Dan Li, Li-Na Yang, Jie-Yi Lin, Yong-Zhong Wu, Zheng Tang, Hong-Lei Tu, Xin Zhang, Yun-Chang Liu, Meng-Qi Yang, Nuo-Han Wang, Jiang-Dong Sui, Hai-Qiang Mai & Ying Wang. (2023) Eosinophil dynamics during chemo-radiotherapy correlate to clinical outcome in stage Ⅱ-Ⅳa nasopharyngeal carcinoma patients: Results from a large cohort study. Radiotherapy and Oncology 188, pages 109900.
Crossref
Katsuhiro Ito, Yuki Kita & Takashi Kobayashi. (2022) Real‐world outcomes of pembrolizumab for platinum‐refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial‐unfit patients. International Journal of Urology 30:9, pages 696-703.
Crossref
Lin Liang, Chanjuan Cui, Dan Lv, Yiqun Li, Liyan Huang, Jiayu Feng, Tao An, Pengchao Tian, Ke Yang, Linjun Hu, Lizhen Gao, Jian Zhang, Yuhui Zhang, Fei Ma & Yanfeng Wang. (2023) Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity. ESC Heart Failure 10:3, pages 1907-1918.
Crossref
Tatsushi Kawada, Takafumi Yanagisawa, Hadi Mostafaei, Reza Sari Motlagh, Fahad Quhal, Pawel Rajwa, Ekaterina Laukhtina, Markus von Deimling, Alberto Bianchi, Mohammed Majdoub, Maximilian Pallauf, Benjamin Pradere, Jeremy Yuen-Chun Teoh, Pierre I. Karakiewicz, Motoo Araki & Shahrokh F. Shariat. (2023) Impact of Performance Status on Oncologic Outcomes in Patients with Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitor: A Systematic Review and Meta-analysis. European Urology Focus 9:2, pages 264-274.
Crossref
Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Yoshifumi Hori, Toshihisa Tomoda, Mirii Harada, Shingo Tamura, Hiroki Kobayashi, Yamato Wada, Kentaro Kuroiwa, Narihito Seki, Naohiro Fujimoto & Motonobu Nakamura. (2022) The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status. OncoTargets and Therapy Volume 15, pages 1321-1330.
Crossref
Sharon Grisaru-Tal, Marc. E. Rothenberg & Ariel Munitz. (2022) Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nature Immunology 23:9, pages 1309-1316.
Crossref